Teva has launched 2 new generic drugs in the US
Posted on Mar 28, 2018 by Ifi Reporter - Dan Bielski
Teva Pharmaceutical Industries has announced the launch of two new generic drugs in the US.The largest launch of the drug is Lialda (mesalamine), which is used to treat mild to moderate ulcerative colitis, Of the product portfolio of Actibis, which was acquired in 2016.
The annual sales of the drug in the US stood at about $ 1.1 billion a year, as of January 2018. This is a drug originally manufactured by the pharmaceutical company Shire, and an earlier generic version was approved in 2017 for Zydus.
Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. The drug is also used to prevent nausea and vomiting in the 24 hours after surgery. Teva's sales in the year ended November 2017 amounted to $ 459 million, and Teva Pharmaceutical Industries Ltd.
Articles Archive
Top Categories
ABOUT IFI TODAY
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum